Heightened Competition for Redcare Pharmacy as German Retail Giant Enters Online Market

Redcare Pharmacy NL0012044747

The competitive landscape for Germany's online pharmacies has intensified with a significant new player. The drugstore chain dm has officially launched its "dm-med" service, entering the market for both prescription and over-the-counter medications. This move places additional pressure on established online operators like Redcare Pharmacy, which now faces heightened rivalry in a sector already known for thin margins. A central question emerges: can the company maintain its current pricing, or will it be forced to respond to dm's aggressive low-price strategy?

In response to the launch, UBS has issued its assessment. Market researcher Olivier Calvet at the firm has reaffirmed a "Neutral" rating on Redcare's stock, maintaining a price target of 74 euros. He characterized dm's move as a "long-anticipated market entry," noting that Redcare appeared significantly more active than its rival DocMorris in the fourth quarter. This activity is seen as an effort to bolster customer loyalty and market position ahead of the new competition.

The core issue, from UBS's perspective, is pricing. The dm-med platform is built on a "permanent low-price" concept and offers approximately 2,500 pharmacy-exclusive products. Its logistics are handled from a distribution center in Bor, Czech Republic—a cross-border model structurally similar to Redcare's own operations.

Despite the news, the market's initial reaction has been muted. Redcare shares have recently stabilized just above 63 euros. However, this price remains more than 50% below the stock's 52-week high, indicating that considerable skepticism is already priced in.

Redcare's Countermeasures: Expansion and New Leadership

Alongside these external challenges, Redcare is executing its own strategic initiatives. On December 11, the company inaugurated a new online pharmacy unit in the Czech Republic, specifically designed to serve the Austrian market. The goal is to shorten delivery times within the DACH region and enhance logistical efficiency—a critical factor as price pressure mounts and every basis point of margin becomes crucial.

The company's financial leadership has also changed. Since December 1, Hendrik Krampe has assumed the role of Chief Financial Officer. He brings e-commerce experience from senior positions at Amazon and eBay. Expectations are that he will prioritize scalability and cash flow management, even as continued investment in marketing and infrastructure remains essential to compete with dm and DocMorris.

A Structural Market Shift

dm's entry represents a structural shift in the competitive environment. Until now, the field of cross-border online pharmacies for German customers was primarily contested by Redcare (formerly Shop Apotheke) and DocMorris. dm enters with a distinct advantage: millions of existing loyal customers from its physical stores, an established app, and a powerful mass-market brand.

This altered landscape directly impacts key commercial metrics:
* Customer Acquisition Costs (CAC): A significant portion of dm's traffic may flow through its existing customer channels, potentially lowering marketing spend per new customer—a disadvantage for pure online players.
* Average Order Value: The ability for customers to combine medication with general drugstore items could increase average basket sizes—a lever not available to Redcare in the same way.
* Margin Pressure: Aggressive low-price strategies increase sector-wide pressure, likely leading to more frequent discounts and promotions.

The relatively calm reaction of Redcare's share price suggests the market was prepared for dm's launch. However, recent volatility in the days preceding the debut indicates investors will be highly sensitive to any early signals of actual customer migration.

The Crucial Fourth Quarter and Key Metrics

All eyes now turn to Redcare's upcoming Q4 update, scheduled for early January 2026. Three key performance indicators will be under particular scrutiny:

1. Customer Acquisition Costs (CAC): Whether marketing expenditures surged in December to complicate dm's market entry.
2. Growth in Active Customers: Whether Redcare can continue to add customers, especially in the prescription segment, despite the new competitor.
3. Gross Margin: Whether price matching or counter-offers are already exerting downward pressure on profitability.

From a technical analysis standpoint, the price zone around 62 euros remains a critical support level. As long as this level holds and UBS's substantially higher 74-euro price target stands, the next significant move for the stock will likely depend on the hard data released in January. Specifically, the market will be looking for any early evidence of dm's impact on Redcare's costs, growth, and margins.